Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data

Results of a new analysis of real-world data—including 589 patients with ruxolitinib-treated myelofibrosis—showed that 65 patients (11%) developed myeloid blast phase, of which 61 patients discontinued ruxolitinib at blast phase diagnosis, at a median period of 1.2 years (range, 0.1-6.8) after starting the therapy. Incidence of transformation to blast phase was significantly lower in intermediate-1 risk patients compared with intermediate-2/high-risk patients. After a median follow-up of 3 years from ruxolitinib start, rates of transformation in patients with primary and secondary myelofibrosis were comparable.